Efficacy and Safety of MOX/ALB vs. IVM/ALB Co-administration

Inclusion Criteria: * Aged between 12 and 19 years. * Written informed consent signed by either parents/caregivers for underage adolescents (aged 12-17 years) or by the participant him/herself (18-19 years of age); and written assent by underage participant. * Agree to comply with study procedures, including provision of two stool samples at the beginning (baseline) and on three follow-up assessments (14-21 days, 5-6 weeks and 3 months after treatment). * Willing to be examined by a study physician prior to treatment. * At least two slides of the quadruple Kato-Katz thick smears positive for T. trichiura and infection intensities of at least 48 EPG. Exclusion Criteria: * No written informed consent by individual or caregiver and/or no written assent by minors * Presence or signs of major systemic illnesses, e.g. body temperature ≥ 38°C, severe anemia (below 80g/l Hb according to WHO) upon initial clinical assessment. * History of acute or severe chronic disease. * Recent use of anthelmintic drug (within past 4 weeks). * Attending other clinical trials during the study. * Pregnancy, lactating, and/or planning to become pregnant within the next 6 months. * Known allergy to study medications (i.e. albendazole, ivermectin or moxidectin). * Taking medication with known interaction on study drugs.